Lixte's LB-100 Shows Early Promise in Ovarian Cancer Trial
Event summary
- Lixte presented interim results from a Phase 1/2 trial combining LB-100 with dostarlimab at the Society of Gynecological Cancer conference (April 10-13, 2026).
- 20 patients evaluated showed a 40% disease control rate with median OS not yet reached at 12 months.
- A second cohort of 21 patients is enrolling with higher LB-100 exposure based on favorable interim results.
The big picture
The results represent an important validation of Lixte's activation lethality approach in a challenging cancer indication with limited treatment options. The combination strategy targets a specific molecular vulnerability in ovarian clear cell carcinoma, potentially expanding the patient population that could benefit from immune checkpoint inhibitors. Success here could position LB-100 as a foundational component in future ovarian cancer treatment paradigms.
What we're watching
- Clinical Validation
- Whether the expanded cohort can confirm and extend the interim efficacy signals seen in the initial patient group.
- Regulatory Pathway
- How these results might position LB-100 for potential accelerated development pathways in ovarian clear cell carcinoma.
- Competitive Positioning
- The pace at which Lixte can differentiate its PP2A inhibition approach from emerging alternatives in immunotherapy combination strategies.
Related topics